Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (December 2020)
22 slides from Medical Developments International's investor presentation, Dec 14, 2020
Slide 1: MVP Capital Raising Presentation
MVP Capital Raising Presentation 14 December 2020
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer IMPORTANT NOTICE AND DISCLAIMER The following notice and disclaimer applies to this investor presentation (Presentation or document) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information con
Slide 3: Important Notice and Disclaimer (continued)
Important Notice and Disclaimer (continued) Effect of rounding A number of figures, amounts, percentages, estimates and calculations of value in this Presentation are subject to the effects of rounding. Past performance Investors should note that past performance and pro forma financial information
Slide 4: Executive Summary
Executive Summary • MVP is pleased to welcome two highly experienced and credentialed pharmaceutical executives: Incoming Chairman • Gordon Naylor (ex-Seqirus, CSL) as Non-Executive Chairman and CEO • Brent MacGregor (ex-Seqirus, CSL, Novartis, Sanofi) as Chief Executive Officer • Sales conditions c
Slide 5: Incoming Chairman and CEO
Incoming Chairman and CEO Gordon Naylor, Non-Executive Chairman (effective 18 December 2020) Gordon has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was est
Slide 6: Trading update
Trading update • Transition arrangements for taking back the distribution rights from Mundipharma in the EU are progressing to plan. • Sales to date for the half are generally subdued and below prior year, for the following key reasons: • Following an early COVID pandemic surge in sales, the mild co
Slide 7: Penthrox®
Penthrox® A world class opportunity • Market leader for trauma pain • Non-opioid fast-acting inhaled analgesic • 85% of patients reach clinical analgesia within 6-10 breaths1 • Demonstrated safety and efficacy profile for 40+ years • Manufactured in Australia 1 Coffey (2014)- STOP!: A Randomised, Do
Slide 8: Penthrox is licensed across the world, but our near-term focus is Europe
Penthrox is licensed across the world, but our near-term focus is Europe 8
Slide 9: EU uptake has not matched Australian benchmark
EU uptake has not matched Australian benchmark Irish market leads the efforts, thanks to adoption by all Ambulance services 11000 10015 8250 5912 5500 2750 623 740 277 0 Units/Million inhabitants UK Ireland Australia France Europe 9
Slide 10: Strategic change to unlock EU potential
Strategic change to unlock EU potential Key learnings and recommendations to drive growth In-hospital not the game changer: focus on ambulance services to drive growth It’s not just about reimbursement: get Penthrox on the protocols (national, regional, hospital) Define a commercial strategy for eac
Slide 11: Penthrox® in USA
Penthrox® in USA FDA Update Pre Clinical Study Human Factors Study The Device Clinical • FDA requires a pre- • FDA requires a Human • Device testing • FDA Type C meeting clinical study, which Factors Study to underway scheduled in Jan 2021 mimics the human explore any Health to discuss the clinical
Slide 12: New Penthrox® Inhaler 'Selfie'
New Penthrox® Inhaler ‘Selfie’ 12
Slide 13: Outlook
Outlook MVP’s ambition is to replicate the Australian success in analgesia and respiratory internationally, while capturing a greater share of the full margin on sales. Over the next 12 months+ we expect to: • Continue the growth and learning in our Domestic Market with extended uses and customers f
Slide 14: Capital raising overview
Capital raising overview Placement and Share Purchase Plan to raise up to $30m Institutional Placement A non-underwritten institutional placement of New Shares to eligible investors to raise approximately $25.0m • A non-underwritten share purchase plan is available to eligible MVP shareholders on th
Slide 15: Indicative timetable
Indicative timetable* Event Date / Time Trading halt Before 10am, Thursday, 10 December 2020 Record date for SPP 7pm Sydney time, Friday, 11 December 2020 Announcement of completion of Placement and recommencement of Before 10am, Monday, 14 December 2020 trading Settlement of New Shares issued under
Slide 16: Appendix A – Key Risks
Appendix A – Key Risks This section includes details of the key risks attaching to an investment in shares in MVP. These risks may affect the future operating and financial performance of MVP and the value of MVP shares. Before deciding whether to invest in MVP shares, you should consider whether su
Slide 17: Appendix A – Key Risks (cont.)
SPECIFIC RISKS OF AN INVESTMENT IN MVP (cont.) Appendix A – Key Risks (cont.) Product Safety and Liability Product safety or quality failures, actual or perceived, or allegations of product contamination, even when false or unfounded, could tarnish the image of MVP’s brands and could cause consumers
Slide 18: Appendix A – Key Risks (cont.)
SPECIFIC RISKS OF AN INVESTMENT IN MVP (cont.) Appendix A – Key Risks (cont.) Reliance on Key Management MVP, and each of its businesses, depend substantially on its key management, the loss of whose services might significantly delay or prevent the achievement of its business strategy. The ability
Slide 19: Appendix A – Key Risks (cont.)
SPECIFIC RISKS OF AN INVESTMENT IN MVP (cont.) Appendix A – Key Risks (cont.) Climate Change There has been an increased frequency of natural disasters globally in recent years and it is expected that this trend will continue in the medium to long term. MVP is exposed to a number of potential climat
Slide 20: Appendix A – Key Risks (cont.)
2. GENERAL RISKS AND OFFER RISKS Appendix A – Key Risks (cont.) Market and an investment in Shares The market price of MVP’s shares will fluctuate due to various factors, many of which are non-specific to MVP, including the number of potential buyers or sellers of MVP shares on the ASX at any given
Slide 21: Appendix B – Foreign Selling Restrictions
Appendix B – Foreign Selling Restrictions This document does not constitute an offer of New Shares of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outsid
Slide 22: Medical Developments International
Medical Developments International
Medical Developments International — Investor Presentation (December 2020) on 6ix